Top 4 Companies in the Deferasirox Industry, Execution of Organic and Inorganic Strategies

Deferasirox, which primarily functions as an iron chelator, is used to help individuals with chronic iron overload and excess. This is mostly used for people who have received repeated blood transfusions for serious illnesses like beta-thalassemia and chronic anemia. It also goes by the names Jadenu, Exjade, Defrijet, Desife, and Desirox, and is marketed under all of these names. Combining iron atoms and eliminating them through fecal excretion, aids in the removal of extra iron.

Considering these factors, the market for deferasirox is expected to project a moderate CAGR over the forecast period. Business Research Insights states that the market could reach a valuation of USD 3.72 billion with a 4.5% CAGR from 2022 to 2028. 

The market will grow more quickly if research and development efforts are increased and there are more goods in the pipeline. The rise of chronic illness among people also presents an excellent opportunity for the advancement of the deferasirox industry.

Business Research Insights Presents the Top 4 Companies in the Deferasirox Industry 


Based in Basel Switzerland, Novartis is one of the largest multinational pharmaceutical corporations in the world. The company aims toward reimagining medicine to improve people’s health and deliver its products worldwide. They plan to systematically incorporate approaches in their research, delivery, and development of medicine.

Natco Pharma

An international pharmaceutical firm and a key player in the market for deferasirox, Natco Pharma is located in India. The business produces active medicinal components, agricultural health science products, contract manufacturing services and final dosage formulations. It is a significant manufacturer of branded oncology medications and hepatitis C medications. The company concentrates on creating sophisticated medications at competitive prices. Natco's division for crop health sciences was established in 2019.

Sun Pharma 

With annual revenues of more than US$ 5.1 billion, Sun Pharmaceutical Industries Ltd. (Sun Pharma) is one of the largest specialty generic pharmaceutical firms in the world. With the help of more than 40 production facilities, we supply more than 100 nations with high-quality, reasonably priced medications that are dependable among patients and medical experts.


The company works continuously to make sure that reasonably valued and superior quality medicines are provided to patients. For the past several decades, patients and medical experts all around the globe have trusted them sates the company.

The foundation on which Cipla as an organization has been constructed is care. Their overarching goal has always been caring for life. They have stretched their footmark to several countries and provided more than 1,500 medications across numerous therapeutic categories in more than 50 dosage forms, all of which are motivated by the same goal. They are expanding their footprint in key areas including South Africa, India and the United States along with other developing countries' economies in a determination to make healthcare more accessible globally.

Techniques Companies are Focusing for Distributing of the Product

The main players in the market are currently concentrating on putting both organic and inorganic tactics into practice, which is causing the market for deferasirox to grow more quickly. Several businesses are significantly growing their sales and market share by utilizing both tactics. Product approvals, patents, promotional activities, well-researched treatments, and high-quality product releases are examples of organic growth tactics.

Why it is Important in Medicines?

Many people today deal with chronic illnesses that necessitate large numbers of repeated blood transfusions. While many others get thalassemia symptoms that are not transfusion dependent. The removal of the patients' bodies' excess iron content is absolutely essential. One such medication that is frequently used to treat patients with such conditions is this product

The number of people receiving blood transfusions has been on the rise during the last few years. As a result, there has been a direct demand for the product on a global scale, which has been the main reason propelling the deferasirox industry’s expansion. With the rising demand, there should be plenty of profitable development chances in the market.

Extensive Research and Innovation is the Future of this Product

This product and its possible uses are the subjects of extensive research, which will open up significant market opportunities. Innovation and product improvement are also results of ongoing R&D. It typically has a half-life of 8 to 16 hours. This allows for a single daily dose. But in recent years, there has been a lot of research that has made it possible to gradually extend the time between doses of this medication, which is now being done.

To boost the sustainability of this product, scientists and chemists are now creating better goods with longer expiration dates and increased shelf lives. Because of this, the cost of manufacturing is reduced, which eases the financial load on customers.